News Releases



Advanced Search

NOV 11, 2020

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

NOV 5, 2020

Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences

AUG 21, 2020

Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AUG 18, 2020

Inhibrx Announces Pricing of Initial Public Offering of Common Stock

JAN 8, 2020

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40





